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Abstract
Background: Current guidelines highlight the importance of accurate staging in the management and
prognostication of high risk primary prostate cancer. Conventional radiologic imaging techniques are insufficient to
reliably detect lymph node metastases in prostate cancer. Despite promising results, there is limited published data
on the diagnostic accuracy of PSMA PET-CT to assess local nodal metastases prior to radical prostatectomy.
This study aims to assess the diagnostic efficacy of 68Ga PSMA PET-CT in local lymph node staging of high risk
primary prostate cancer when compared to histopathological findings following radical prostatectomy with pelvic
lymph node dissection.
Methods: We retrospectively analysed consecutive patients with high risk primary prostate cancer referred by
urologists for primary staging PSMA PET-CT using a 68Ga-labeled PSMA ligand, Glu-NH-CO-NHLys-(Ahx)-[HBEDD-
CC], from October 2015 to October 2017. The scans of patients who underwent radical prostatectomy with pelvic
lymph node dissection were interpreted by the consensus reading of two experienced nuclear medicine physicians
blinded to clinical and histopathological data. The contemporaneous records of the referring urologists were
retrospectively reviewed for noteworthy unexpected PET findings that altered their personal preference for surgical
management.
Results: Seventy-one patients were recruited and analysed. PSMA PET-CT showed findings compatible with local
disease in 47 patients (66.2%), lymph node metastases in 10 patients (14.1%) and distant metastases in 14 patients
(19.7%). Twenty-eight patients (twenty-seven of whom had local disease only) underwent surgery yielding 214
lymph nodes, all of which were negative on histopathological analysis. On a node-based analysis, 213 of 214 lymph
nodes were accurately identified as negative for disease with a negative predictive value of 100%. 11 patients had
unexpected PET findings contemporaneously documented by urologists to alter their preference for surgical
management.
Conclusions: PSMA PET-CT appears to have a high negative predictive value for local lymph node metastases in
high risk primary prostate cancer when compared to histopathological findings following radical prostatectomy
with pelvic lymph node dissection.
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Background
When employed in appropriately selected patients, rad-
ical prostatectomy (RP) with or without pelvic lymph
node dissection (PLND) and/or additional multimodal
therapy offer potential cure for prostate cancer (PCa). At
present, controversy remains regarding how best to indi-
vidualise treatment and select candidates for surgical
therapy which often relies on risk-adapted nomograms.
Current guidelines highlight the importance of accurate
staging in the management and prognostication of high
risk primary PCa [1].
Conventional imaging strategies for PCa rely on non-
specific size criteria to define abnormal local lymph
nodes despite 80% of lymph node metastases not meet-
ing the standard 8 mm threshold2. As such, the gold
standard for lymph node staging remains extended pel-
vic lymph node dissection. For practical reasons how-
ever, not all patients are candidates for or elect to
undergo operative management. Furthermore, extended
PLND can be associated with an overall complication
rate of up to 20% [1].
Prostate specific membrane antigen (PSMA) Posi-
tron Emission Tomography-Computed Tomography
(PET-CT) is emerging as a powerful new staging tool
that is being rapidly adopted into clinical practice.
PSMA is a type II transmembrane protein seen in the
prostate which is expressed more strongly in the set-
ting of cancer. Although 5–10% of PCas may not ex-
press PSMA, studies have demonstrated that 98% of
lymph node metastases express PSMA [2, 3]. The use
of PSMA PET-CT has been most widely studied in
the setting of biochemical recurrence (BCR) of PCa. A
systematic review found few high-quality studies inves-
tigating the use of PSMA PET-CT in the primary sta-
ging of high risk patients despite appearing to
outperform conventional imaging modalities [4]. Fur-
thermore, a recent study has shown that when used
in the primary staging of intermediate and high risk
PCas, management was altered in 21% of patients
when compared with conventional imaging strategies
[2, 5, 6]. To date, there have been several studies
assessing the diagnostic performance of PSMA PET-
CT in detecting lymph node metastases in the setting
of primary prostate cancer with histopathological con-
firmation. The reported sensitivity has ranged from 33
to 84%, specificity from 84 to 100%, positive predictive
value from 61.5–100% and negative predictive value
from 69 to 98% [7–11].
Our aim was to assess the diagnostic efficacy of
68Ga PSMA PET-CT in the local lymph node sta-
ging of high risk primary prostate cancer when com-
pared to histopathological findings after radical
prostatectomy with pelvic lymph node dissection
(RP-PLND).
Methods
We conducted a retrospective review of consecutive pa-
tients from October 2015 to October 2017 with high risk
PCa referred independently by urologists employed at
our institution (Liverpool Hospital, Sydney, Australia)
for primary staging PSMA PET-CT scans using a
68Ga-labeled PSMA ligand, Glu-NH-CO-NHLys-(Ahx)-
[HBEDD-CC]. During the study period, referrals were
typically made after conventional imaging had already
been acquired and reviewed. Risk assessment was based
on the European Association of Urology (EAU) risk
groups for BCR of localised and locally advanced PCa
since they are widely adopted in Australian clinical prac-
tice. High risk was defined as Prostate Specific Antigen
(PSA) > 20 ng/mL or Gleason Score (GS) > 7 or TNM
Stage cT2c or greater [1]. Patients being treated for a
synchronous cancer were excluded. Patients who under-
went RP-PLND either alone or as part of multimodal de-
finitive therapy were selected for further analysis. The
template for PLND was left to discretion of the surgeon
as was the decision to perform the procedure with
robotic assistance. Surgeons were not blinded to the re-
sults of the PSMA PET-CT scan. Treatment and follow-
up were not necessarily performed at our institution. In
order to highlight noteworthy cases, the contemporan-
eous records of the referring urologists were retrospect-
ively reviewed for unexpected PET findings that were
documented to alter their personal preference to offer or
decline surgery. In October 2019, our local database was
examined for available follow-up data on patients man-
aged surgically within our health service.
All studies were acquired on a GE-Discovery-710
time-of-flight PET-CT Scanner. The target dose was 2
MBq/kg (dose range: 80-200MBq). The PET studies
were acquired in 3D mode for a total acquisition time of
1.5–2.5 min per bed position adjusted according to the
patient weight, from midbrain to proximal femora at
about 45–60min post injection. Transmission scans and
attenuation corrections were obtained by a 64-slice CT,
using helical mode without the use of a contrast
medium. CT images were acquired at 3.75 to 5 mm slice
thickness and reconstructed to a transaxial matrix size
of 512 × 512. The current (30–40 mAs) and voltage
(120–140 kV) were varied according to the patient
weight. The PET images were reconstructed using GE
VUE Point FX (Time of Flight) algorithm into a 256 ×
256 matrix size with a slice thickness of 3.75 to 4.0 mm.
Patients were routinely administered 20mg frusemide
intravenously at the time of PSMA injection.
The scans of patients who underwent RP-PLND were
interpreted by the consensus reading of two experienced
nuclear medicine physicians blinded to prior clinical, im-
aging and histopathological data. Discrepant interpreta-
tions were resolved by a third experienced Nuclear
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Medicine Physician. Visual and quantitative analyses were
performed on an Advantage Workstation using the PET-
VCAR (Volume-Computer-Assisted-Reading) software.
For each scan, the Nuclear Medicine Physicians identi-
fied suspicious lesions visually using the criteria outlined
by Fanti et al. [12]. They defined ‘anomalous uptake’ as
any uptake higher than adjacent background at sites not ex-
pected to show physiologic uptake (including lacrimal and
salivary glands, liver, spleen, small intestine, colon, kidneys
and coeliac ganglia). ‘Pathologic uptake’ was defined as any
anomalous uptake which is not better explained by another
cause and is suggestive of prostate cancer.
The reference standard for this study was histopatho-
logical confirmation using a node-based analysis. Histo-
pathological findings were reported at several different
pathology centres. Data was collected from the available
local electronic medical records and the private practices
of the referring urologists. We performed a descriptive
analysis of the data.
Results
Seventy-four patients were referred by urologists for
PSMA PET-CT scans between October 2015 to October
2017 for primary staging of high-risk prostate cancer
(Fig. 1). Three patients were excluded due to the pres-
ence of synchronous cancers. PSMA PET-CT showed
findings compatible with local disease in 47 patients
(66.2%), lymph node metastases in 10 patients (14.1%)
and distant metastases in 14 patients (19.7%).
Twenty-eight patients underwent RP-PLND including
twenty-seven patients with local disease only and one
patient with local nodal disease in a single 4 mm right
internal iliac lymph node with maximum Standardised
Uptake Value of 4.1. Table 1 describes the baseline
characteristics of the patients who underwent RP-
PLND. A total of 214 lymph nodes were retrieved at
surgery, all of which were negative on histopathological
analysis. 213 of 214 lymph nodes were accurately identi-
fied as negative for disease using PSMA PET-CT with a
negative predictive value of 100% using a node-based
analysis. On a patient-based analysis, 27 of 28 patients
had accurate lymph node staging using PSMA PET-CT.
Table 2 summarises noteworthy cases in which unex-
pected PSMA PET-CT findings were contemporan-
eously documented to alter the individual urologist’s
preference to offer or decline surgical management. This
included 9 patients who were up-staged by the PET scan
and 2 patients who were down-staged and subsequently
underwent RP-PLND.
By October 2019, the single patient who had nodal dis-
ease on the staging PSMA PET-CT scan prior to RP-
PLND was the only patient to have had imaging-proven
recurrence on a subsequent PET scan at our institution.
BCR was seen at 8 months post-operatively and a repeat
PET scan at 20 months (with PSA 0.9 ng/mL) showed
multiple PSMA-avid pelvic lymph nodes, including in
Fig. 1 Flow chart of treatment for EAU high risk primary prostate cancer patients. RP-RPLND, Radical prostatectomy with pelvic lymph
node dissection
Table 1 Baseline characteristics of twenty-eight patients who
underwent RP-PLND
Median age in years at time of scan (range) 69 (46–82)
Gleason Score: median (range) 8 (6–9)
Prostate Specific Antigen (ng/mL): median (range)* 8 (3–51)











*Data was not available for one patient
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the right internal iliac region where lymph node metas-
tases were seen on the initial staging scan.
Follow-up data was available in our local health service
database for seventeen patients in October 2019. Mean
duration of follow up was 22.8 months (range 6–37
months). There were four cases of BCR, including the
aforementioned case, with a mean time to BCR of 11
months and a range of 8–18 months. There were also
four cases of rising PSA treated with early salvage radio-
therapy at low PSA levels (< 0.1 ng/mL). Mean time to
rising PSA was 20.8 months (range 17–23months).
Discussion
We found that PSMA PET-CT had a high negative pre-
dictive value for primary staging of local lymph nodes in
patients with high risk PCa compared to histopatho-
logical findings after RP-PLND. These results compared
favourably to what has been previously reported in the
literature [7–11]. Moreover, given that the estimated risk
of positive lymph nodes in all high risk PCa patients
treated with RP-PLND is 15–40%, a negative PSMA
PET-CT scan appeared to select a subgroup that were
less likely to have local lymph node involvement at sur-
gery than existing risk nomograms would predict [1]. It
is worth noting that due to the retrospective nature of
our study, surgical lymph node dissection templates
were not standardised prior to the study. With respect
to the patient who underwent RP-PLND with nodal dis-
ease on the staging PSMA PET-CT scan, it is possible
that the lymph node was not taken during PLND given
that nodal metastases were seen in the same lymph node
region on the post-operative PET scan.
Since almost all patients managed operatively in our
study had no lymph node metastases on the PSMA
PET-CT and no positive lymph nodes were retrieved
at surgery, it was not possible to meaningfully assess
broader statistical measures of diagnostic performance
such as sensitivity and specificity compared to histo-
pathology. Furthermore, in the absence of histopatho-
logical correlation in the large number of patients who
did not undergo operative management, assessment of
PSA remission and long-term outcome data could act
as a surrogate gold standard for PET-CT performance.
Importantly, the observed instances of BCR would
suggest that very small volume and micrometastatic
disease remain beyond the detectable threshold of
PET-CT despite the histopathological concordance in
this study. This makes sense given the intrinsically
limited spatial resolution of PET-CT imaging although
alternative radiopharmaceuticals, such as newer gener-
ation 18F-labelled PSMA compounds, may provide in-
cremental improvements in performance. Determining




Pre-PET TNM Stage Urologist’s Pre-PET Prefer-
ence To Offer Surgery
Post-PET
TNM Stage
Unexpected PET Finding Treatment Performed
1 M1a (para-aortic
lymph nodes)
Decline N0M0 No lymph node PSMA uptake RP-PLND
2 N0 M0 Offer N1M1a Non-regional lymph node metastases
(extending above diaphragm)
Systemic therapy
3 T3M1b (lumbar spine
and iliac bone)
Decline N0M0 No bony PSMA uptake RP-PLND




5 T3aN0M0 Offer N0 M1 Solitary vertebral metastasis Whole pelvis radiotherapy,
hormone therapy, stereotactic
radiotherapy to metastatic deposit
6 T3aN0M0 Offer N1 M0 Presacral and internal iliac lymph
node metastases
Whole pelvis radiotherapy and
hormone therapy
7 T2cN0M0 Offer N1M1b Non-regional lymph node and
bony metastases
Systemic therapy
8 T1 N0M0 Offer N1,
possible
M1b
Local lymph node metastases and
possible iliac bone PSMA uptake
Whole pelvis radiotherapy and
hormone therapy
9 T3 N1M0 Offer N1M1b Non-regional lymph nodes and
multiple bony metastases
Hormone therapy
10 T2cN0M0 Offer N1M1b Non-regional lymph nodes and
bony metastases
Hormone therapy
11 T3 N0M0 Offer N1M1a Non-regional lymph node
metastases
Hormone therapy
RP-RPLND Radical prostatectomy with pelvic lymph node dissection
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the clinical significance of the PSMA PET-CT findings
requires longer term follow-up.
The role of PSMA PET-CT in the management of
high risk PCa patients remains the subject of ongoing re-
search. Our study highlighted a number of contempor-
aneously identified examples where the individual
surgeon’s preference to offer surgical management was
significantly altered by unexpected findings on the
PSMA PET-CT scan, predominantly up-staging patients
who may have avoided unnecessary surgery based on
conventional imaging alone. In a recent multicentre pro-
spective Australian study, PSMA PET-CT demonstrated
a change in all-modality management intent of 21% in a
cohort of both intermediate and high risk primary pros-
tate cancer. The impact in the setting of BCR was sig-
nificantly greater at 62% [6]. The long-term clinical
outcomes and financial impact of these findings could
be the subject of future analysis.
Our study was performed in a single centre with experi-
enced nuclear medicine physicians following standardisa-
tion of interpretation criteria using the proposals by Fanti
et al. [12]. Unlike FDG PET-CT where internal reference
standards such as uptake in the blood pool or liver can as-
sist in interpretation, no consensus guidelines for standar-
dised reporting criteria exist in PSMA PET-CT. Reader
experience may also impact the diagnostic performance of
the study. For example, the poorest sensitivity of primary
staging PSMA PET-CT scanning reported in the literature
was 33% however, this study that did not involve special-
ists in reporting PET-CT scans [7].
Conclusions
Our study found that PSMA PET-CT appears to have a
high negative predictive value for local lymph node me-
tastases in patients with high risk primary PCa who
undergo RP-PLND compared to histopathological find-
ings. Ongoing follow-up is needed to assess the long-
term clinical impact of these findings.
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